Peptides for Gut Health

6 research peptides are currently studied for gut health. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

Larazotide (AT-1001) is an innovative synthetic peptide composed of eight amino acids, functioning primarily as a regulator of tight junctions in the intestinal epithelium. This compound is being developed as an adjunctive therapy for individuals with celiac disease, aiming to mitigate the adverse effects of gluten exposure by reducing intestinal permeability, commonly referred to as 'leaky gut.' Larazotide has reached significant milestones, including the completion of Phase II trials and a Phase III trial known as INN-202, also referred to as CeDLara. Notably, its mechanism of action is localized within the gut lumen, minimizing systemic absorption and potential side effects. Originally developed by Alba Therapeutics, the rights to Larazotide were later acquired by Innovate Biopharmaceuticals, now part of 9 Meters Biopharma. The evidence base suggests that Larazotide may effectively alleviate symptoms associated with celiac disease during gluten exposure, although the extent of its impact on long-term gut health requires further investigation.

BPC-157 is a synthetic peptide consisting of 15 amino acids, derived from a naturally occurring protein in human gastric juice. This peptide has garnered attention due to its extensive regenerative and cytoprotective effects observed in numerous animal studies, which have demonstrated its potential in healing various tissues, including tendons, ligaments, muscles, and the gastrointestinal tract. However, while preclinical evidence is robust, human clinical data remain scarce, with only three pilot studies published to date, focusing on conditions such as knee pain and interstitial cystitis. These studies collectively involved a small number of participants, limiting the generalizability of findings. The FDA has classified BPC-157 as Category 2, restricting its compounding, and it is also banned by WADA for use in competitive sports. Although BPC-157 is reported to accelerate healing processes and improve gut lining integrity, further clinical trials are essential to fully understand its therapeutic potential and safety in human subjects.

KPV is a naturally occurring tripeptide composed of lysine, proline, and valine, derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH). This peptide retains the anti-inflammatory and antimicrobial properties of its parent hormone while avoiding activation of melanocortin receptors associated with pigmentation and sexual arousal. Research indicates that KPV can suppress the activation of NF-κB, a key player in inflammatory responses, and it is transported into intestinal epithelial cells via the PepT1 transporter, which is upregulated during periods of gut inflammation. This self-targeting mechanism enhances its therapeutic potential in inflammatory conditions. Notably, KPV's small molecular size contributes to its oral bioavailability, a characteristic that is relatively rare among peptides. As of April 15, 2026, KPV was removed from FDA Category 2, indicating an evolving regulatory landscape. Current preclinical studies support its role in reducing intestinal inflammation, although further research is needed to confirm these effects in clinical settings.

Chonluten (Glu-Asp-Gly, EDG) is a synthetic tripeptide that belongs to the Khavinson bioregulatory peptide family. Specifically designed as a bioregulator for the mucosal epithelium of both respiratory and gastrointestinal tracts, Chonluten aims to restore mucosal barrier function and promote epithelial regeneration in aging or damaged tissues. Most of the research surrounding Chonluten has been published in Russian biogerontology literature, indicating a focus on its potential applications in enhancing mucosal health. However, the lack of extensive clinical trials in humans limits the understanding of its efficacy and safety profile. Given the current evidence, Chonluten may hold promise for improving mucosal integrity, but further studies are necessary to validate its therapeutic claims and determine its applicability in broader clinical contexts.

Ovagen (Glu-Asp-Leu) is a synthetic tripeptide developed as part of the Khavinson bioregulator series, targeting the normalization of liver and gastrointestinal function through tissue-specific gene regulation. While the theoretical basis for its action suggests potential benefits for liver health and gastrointestinal performance, the existing evidence remains limited. Most of the supporting data comes from the Khavinson bioregulator programme, which has not been extensively validated through rigorous clinical trials. This lack of robust evidence makes it challenging to draw definitive conclusions regarding the efficacy and safety of Ovagen in humans. As such, further research is warranted to explore its potential applications and to substantiate any claims regarding its impact on gut health and related functions.

Uroguanylin is a 16-amino-acid peptide hormone primarily produced in the intestines, where it plays a crucial role in activating guanylate cyclase C (GC-C) receptors located on epithelial cells. This activation is instrumental in regulating intestinal fluid and electrolyte transport, thereby maintaining homeostasis within the gut environment. Furthermore, uroguanylin is gaining attention for its potential involvement in satiety signaling and its protective roles in colorectal cancer prevention. Notably, linaclotide (Linzess), an FDA-approved drug, acts as a synthetic GC-C agonist and shares a similar mechanism of action, highlighting the therapeutic relevance of this signaling pathway. Uroguanylin is being explored as a more physiological alternative to synthetic agents, which may offer a more natural modulation of gut function. However, the evidence supporting uroguanylin's efficacy remains limited, primarily residing within preclinical research, which underscores the need for further studies to elucidate its therapeutic potential and safety profile.